pemetrexed + cisplatin
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer
Conditions
Non-Small-Cell Lung Cancer
Trial Timeline
Nov 1, 2005 → Dec 1, 2007
NCT ID
NCT00259285About pemetrexed + cisplatin
pemetrexed + cisplatin is a phase 2 stage product being developed by Eli Lilly for Non-Small-Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00259285. Target conditions include Non-Small-Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00040625 | Pre-clinical | Completed |
| NCT01000480 | Phase 2 | Completed |
| NCT00887549 | Phase 2 | Completed |
| NCT00895648 | Phase 2 | Terminated |
| NCT00475657 | Phase 2 | Terminated |
| NCT00447421 | Phase 1/2 | Terminated |
| NCT00415168 | Phase 2 | Completed |
| NCT00386815 | Phase 2 | Completed |
| NCT00374868 | Phase 1/2 | Completed |
| NCT00259285 | Phase 2 | Terminated |
| NCT00251550 | Phase 1/2 | Completed |
| NCT00191308 | Phase 2 | Completed |
| NCT00320515 | Phase 1/2 | Completed |
| NCT00190801 | Phase 2 | Completed |
| NCT00087698 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer